Study: Targeted therapy benefits patients with early stage lung cancer
Yale Cancer Center researchers have found that treatment with osimertinib following surgery significantly improves disease-free survival for some patients.
Source: Yale Science and Health News - Category: Universities & Medical Training Source Type: news
More News: Cancer | Cancer & Oncology | Health | Lung Cancer | Science | Study | Universities & Medical Training | Yale